ADC

5개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#antibody-drug-conjugate#NeoadjuvantTherapy+1
Trials 17Status Active
ADCLimited DatastaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, tislelizumab+disitamab-vedotin)

Neoadjuvant Immunotherapy · Neoadjuvant Immunotherapy

#NeoadjuvantImmunotherapy#ADC#Phase2#antibody-drug-conjugate#BeiGene
Trials 17Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveGastricCancer+2
Trials 1Status Active